Armistice Capital adds Pacira Pharmaceuticals Inc (PCRX) to its portfolio

Pacira Pharmaceuticals Inc (PCRX) : Armistice Capital added new position in Pacira Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 268,000 shares of Pacira Pharmaceuticals Inc which is valued at $9,862,400 , the company said in a statement filed on Nov 14, 2016 with the SEC.Pacira Pharmaceuticals Inc makes up approximately 4.02% of Armistice Capital’s portfolio.

Other Hedge Funds, Including , Allianz Asset Management Ag added PCRX to its portfolio by purchasing 53,137 company shares during the most recent quarter which is valued at $1,992,638.Geode Capital Management boosted its stake in PCRX in the latest quarter, The investment management firm added 6,587 additional shares and now holds a total of 300,452 shares of Pacira Pharmaceuticals Inc which is valued at $11,206,860. Pacira Pharmaceuticals Inc makes up approx 0.01% of Geode Capital Management’s portfolio.American Century Companies Inc reduced its stake in PCRX by selling 5,006 shares or 7.54% in the most recent quarter. The Hedge Fund company now holds 61,385 shares of PCRX which is valued at $2,047,190.Nationwide Fund Advisors boosted its stake in PCRX in the latest quarter, The investment management firm added 224 additional shares and now holds a total of 23,816 shares of Pacira Pharmaceuticals Inc which is valued at $781,165.

Pacira Pharmaceuticals Inc closed down -0.55 points or -1.50% at $36 with 9,33,663 shares getting traded on Monday. Post opening the session at $36.75, the shares hit an intraday low of $35.775 and an intraday high of $36.75 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Pacira Pharmaceuticals Inc reported $0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.25 according to the earnings call on Nov 2, 2016. Analyst had a consensus of $-0.05. The company had revenue of $68.40 million for the quarter, compared to analysts expectations of $67.16 million. The company’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS.

Many Wall Street Analysts have commented on Pacira Pharmaceuticals Inc. Shares were Reiterated by Mizuho on Nov 3, 2016 to “Buy” and Lowered the Price Target to $ 46 from a previous price target of $64 .Shares were Reiterated by Wedbush on Oct 19, 2016 to “Outperform” and Lowered the Price Target to $ 93 from a previous price target of $109 .Pacira Pharmaceuticals Inc was Resumed by Brean Capital to “Hold” on Oct 7, 2016.

Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pacira Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pacira Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.